Insulin Analog Characterization for Generic ANDA: Peptide Mapping, Sequencing, and Sameness Strategy

Introduction:

Insulin analog characterization for generic ANDA is one of the most scientifically demanding challenges in the follow-on biologics space. Unlike small-molecule generics where sameness is structurally straightforward, insulin analogs — such as insulin lispro, insulin aspart, insulin glargine, insulin detemir, and insulin degludec — are engineered peptide therapeutics with precise amino acid substitutions, chemical modifications, and complex higher-order structures that are directly linked to their pharmacokinetic and pharmacodynamic profiles.

Under the U.S. FDA’s 505(j) pathway (established by the Biologics Price Competition and Innovation Act and subsequently through the CARES Act, which reclassified insulin products as biologics), sponsors must demonstrate that a proposed generic insulin is the “same” as the reference listed drug (RLD). This goes far beyond demonstrating identical amino acid sequences — it requires a multi-layered analytical strategy that probes primary structure, post-translational modifications, secondary and tertiary structure, higher-order structure, and product-related impurities.

At ResolveMass Laboratories Inc., we have developed a robust analytical platform specifically designed to support generic insulin ANDA submissions, combining state-of-the-art mass spectrometry, chromatography, and structural biology tools to build a compelling, regulatorily defensible sameness argument.

Summary:

• Insulin analog characterization for generic ANDA requires demonstrating sameness through rigorous peptide mapping, sequence confirmation, and higher-order structure analysis.
• The FDA’s 505(j) pathway for insulin products demands a comprehensive analytical sameness strategy, not just bioequivalence data.
• Peptide mapping with LC-MS/MS is the gold-standard technique for confirming primary sequence identity and detecting sequence variants or post-translational modifications.
• Higher-order structure (HOS) tools — including circular dichroism (CD), hydrogen-deuterium exchange (HDX-MS), and NMR — are increasingly expected in regulatory submissions.
• ResolveMass Laboratories Inc. provides end-to-end analytical characterization services tailored to generic insulin ANDA submissions in Canada and globally.

1: What Is a “Sameness” Strategy for Insulin Analogs?

A sameness strategy demonstrates that the generic insulin analog is structurally and functionally identical to the reference product. It typically involves three interconnected pillars:

This strategy must be supported by forced degradation studies, reference standard characterization, and a rigorous analytical comparability exercise between the proposed product and the RLD.

2: Peptide Mapping for Insulin Analog Characterization

Peptide mapping is the cornerstone analytical technique for insulin analog characterization. It confirms the primary amino acid sequence of the drug substance by digesting the intact protein with site-specific proteases (e.g., trypsin, Lys-C, Glu-C), separating the resulting peptides by reversed-phase HPLC, and identifying them by tandem mass spectrometry (MS/MS).

Step-by-Step Peptide Mapping Workflow for Insulin Analogs

1. Sample Preparation: Reduction and alkylation of disulfide bonds (critical for insulin’s three disulfide linkages: A6-A11, A7-B7, A20-B19) followed by denaturation.
2. Enzymatic Digestion: Trypsin digestion (cleaves at Arg/Lys) is most commonly used; Glu-C or Lys-C may be employed for orthogonal coverage. Multi-enzyme digestion increases sequence coverage toward the required ≥95%.
3. LC Separation: Reversed-phase nano-LC or micro-LC with C18 columns optimized for short peptide retention.
4. MS Detection: High-resolution instruments (Orbitrap, Q-TOF) provide accurate mass and MS/MS fragmentation data (b- and y-ion series) for unambiguous sequence assignment.
5. Data Analysis: Sequence coverage calculation, PTM identification, and quantification of peptide variants using specialized software (e.g., Byonic, Proteome Discoverer, MassLynx).
6. Comparability: Side-by-side comparison of peptide maps from the proposed product vs. the RLD for peak pattern, retention times, and mass accuracy.

Key Peptide Map Features Regulators Scrutinize

• Sequence coverage: Typically ≥95% is required; for short peptides like insulin (~51 amino acids), 100% coverage is achievable and expected.
• A-chain and B-chain integrity: Each chain must be individually confirmed; the non-natural amino acid substitutions defining the analog (e.g., ProB28→Lys, LysB29→Pro in lispro) must be unambiguously confirmed by MS/MS fragment ions.
• Disulfide bond mapping: Confirmation of correct disulfide connectivity using non-reduced peptide mapping; incorrect disulfide pairing produces misfolded, inactive protein.
• C-terminal confirmation: Particularly important for analogs like insulin glargine, which carries a unique C-terminal arginine extension on the B-chain and an asparagine-to-glycine substitution at A21.
• Sequence variants: Even low-level sequence variants (e.g., deamidation, oxidation, misincorporation) must be detected and quantified.

3: Sequencing Strategy — Intact Mass and Top-Down Approaches

Intact mass analysis provides the first-pass confirmation of molecular identity and gross structural integrity. Using high-resolution ESI-MS or MALDI-TOF, the measured intact mass of the insulin analog is compared against the theoretical mass calculated from the reference amino acid sequence.

Intact Mass Analysis Parameters for Insulin Analogs

Top-down MS approaches — where intact proteins are fragmented directly in the mass spectrometer without proteolytic digestion — are increasingly valuable for insulin analogs because of their small size. Top-down sequencing can confirm the full sequence, all modifications, and disulfide bond status in a single experiment, making it an orthogonal and highly efficient tool for regulatory submissions.

4: Higher-Order Structure (HOS) Characterization

Higher-order structure analysis demonstrates that the generic insulin analog adopts the same folded conformation as the RLD, which is directly linked to its biological activity. The FDA’s guidance on complex drug substances increasingly expects sponsors to characterize HOS comprehensively.

HOS Techniques Commonly Used in Insulin ANDA Packages

• Circular Dichroism (CD):
  • Far-UV CD (190–250 nm): Probes secondary structure (α-helix content of insulin’s A-chain helices).
  • Near-UV CD (250–350 nm): Probes tertiary structure environment of aromatic residues (Phe, Tyr).
  • Thermal denaturation by CD: Comparability of unfolding thermodynamics (Tm, ΔH).
• Fourier Transform Infrared Spectroscopy (FTIR):
  • Amide I band analysis (1600–1700 cm⁻¹) provides secondary structure fingerprint.
  • ATR-FTIR can analyze formulated drug product directly, useful for comparability of finished dosage form.
• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):
  • Probes backbone amide hydrogen exchange rates as a proxy for protein dynamics and solvent accessibility.
  • Highly sensitive to conformational differences; can detect subtle structural changes not apparent by CD or FTIR.
  • Increasingly requested by FDA reviewers as a confirmatory HOS tool.
• Nuclear Magnetic Resonance (NMR):
  • ¹H-NMR fingerprinting of insulin analogs can detect differences in tertiary structure.
  • 2D NMR (¹H-¹⁵N HSQC) provides residue-level structural resolution but requires ¹⁵N-labeled material.
  • ¹H-NMR is routinely used as a USP identity test for insulin and its analogs.
• Dynamic Light Scattering (DLS) and Analytical Ultracentrifugation (AUC):
  • Characterize the oligomeric state of insulin (monomer, dimer, hexamer) and confirm that the proposed product has the same self-association behavior as the RLD.

5: Impurity Profiling and Product-Related Variants

Comprehensive impurity profiling is essential for both safety and sameness arguments in insulin analog ANDA submissions. Product-related impurities — including desamido insulin, oxidized variants, high-molecular-weight proteins (HMWPs), and truncated sequences — must be detected, quantified, and compared against the RLD.

Key Impurity Categories for Insulin Analogs

Forced degradation studies (heat, light, oxidation, acid/base hydrolysis) are required to demonstrate that the proposed product degrades via the same pathways as the RLD, confirming structural identity and the validity of the analytical methods used.

6: Regulatory Framework for Insulin Analog ANDA Submissions

The regulatory landscape for insulin analog generics is shaped primarily by FDA’s 505(j) pathway, the CARES Act (2020), and associated product-specific guidance documents. Understanding this framework is essential for designing an efficient characterization strategy.

Key Regulatory Documents to Reference

• FDA CARES Act (2020): Reclassified insulin products as biologics under Section 351 of the PHS Act; created a transition pathway for approved insulin ANDAs.
• FDA Product-Specific Guidances (PSGs): FDA has issued individual PSGs for insulin lispro, insulin aspart, insulin glargine, insulin detemir, and others — each specifying recommended analytical methods, reference standards, and sameness criteria.
• ICH Q6B: Specifications for biotechnological/biological products; provides the framework for characterization and specification-setting.
• USP <121>, <125>, <126>, <129>: United States Pharmacopeia insulin-specific chapters covering identity, assay, related proteins, and HMWPs.
• FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products (2014): Structural differences detected in characterization studies must be assessed for their potential immunogenic consequences.

ResolveMass Laboratories Inc. maintains a current library of FDA product-specific guidance documents for insulin analogs and designs all analytical programs in direct alignment with these regulatory expectations.

7: Building a Defensible Sameness Package — ResolveMass’s Integrated Approach

A successful insulin analog ANDA sameness package integrates primary structure data, HOS data, and impurity profiling into a coherent, cross-referenced analytical narrative. At ResolveMass Laboratories Inc., our integrated characterization approach follows a five-stage process:

Stage 1 — Reference Product Analysis: Extensive characterization of multiple RLD lots to establish a reference envelope for all structural attributes.

Stage 2 — Proposed Product Characterization: Full structural characterization of the proposed product using the same analytical platform as Stage 1.

Stage 3 — Side-by-Side Comparability: Statistical and graphical comparison of all structural attributes across RLD lots and proposed product lots; establishment of similarity ranges.

Stage 4 — Forced Degradation & Stability: Confirmation that degradation pathways and degradant profiles are identical, with validated stability-indicating methods.

Stage 5 — Regulatory Documentation: Preparation of the characterization section of the ANDA filing, with clearly structured tables, spectra, and method summaries aligned to FDA reviewer expectations.

Our team includes analytical scientists with direct experience in insulin characterization, regulatory submission writing, and FDA interactions — ensuring that the science and the regulatory strategy are perfectly aligned.

Conclusion:

Insulin analog characterization for generic ANDA is a high-stakes, scientifically intensive discipline that sits at the intersection of analytical chemistry, structural biology, and regulatory strategy. The demand for sequence-confirmed sameness, higher-order structure comparability, and comprehensive impurity profiling means that sponsors cannot rely on generalist analytical laboratories — they need a partner with deep expertise in insulin biology and regulatory science.

ResolveMass Laboratories Inc. brings together the advanced analytical instrumentation, scientific expertise, and regulatory knowledge needed to build a robust, FDA-aligned sameness package for your insulin analog generic program. Whether you are in early development, preparing for a pre-ANDA meeting, or finalizing your submission, our team is ready to support you at every stage.

Frequently Asked Questions:

Reference

• Rogers-Crovak JA, Delaney EJ, Detlefsen DJ. Recommendation for Clarifying FDA Policy in Evaluating “Sameness” of Higher Order Structure for Generic Peptide Therapeutics. The AAPS Journal. 2024 Nov 26;27(1):8.https://link.springer.com/article/10.1208/s12248-024-00994-8
• De Groot AS, Mattei A, Gabriel B, Calderini J, Roberts BJ, Lelias S, McAllister M, Boyle C, Martin W, Richard G. Immunogenicity of generic peptide impurities: current orthogonal approaches. Pharmaceutical research. 2025 May;42(5):805-18.https://link.springer.com/article/10.1007/s11095-025-03843-1
• Jarosinski MA, Chen YS, Varas N, Dhayalan B, Chatterjee D, Weiss MA. New horizons: next-generation insulin analogues: structural principles and clinical goals. The Journal of Clinical Endocrinology & Metabolism. 2022 Apr 1;107(4):909-28.https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/sscp.70057
• Kuril AK, Saravanan K, Subbappa PK. Analytical considerations for characterization of generic peptide product: A regulatory insight. Analytical Biochemistry. 2024 Nov 1;694:115633.https://www.sciencedirect.com/science/article/pii/S0003269724001775

About the Author

Priyal Darji